Cargando…
Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity
The use of modern therapies such as thalidomide, bortezomib and lenalidomide coupled with upfront high-dose therapy and autologous stem cell transplant (ASCT) has resulted in improved survival in patients with newly diagnosed multiple myeloma (MM). However, patients with relapsed/refractory multiple...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827007/ https://www.ncbi.nlm.nih.gov/pubmed/26726946 http://dx.doi.org/10.1038/bmt.2015.307 |